Drug Discovery
By
Did Oncology Approvals in 2025 Reshape the Competitive Landscape—and Set the Stage for a Breakthrough Cycle in 2026?
Global – December 2025 — The oncology sector reached a strategic inflection point in 2025, as a surge…
Phase 3 Clinical Trials of Setrusumab in Osteogenesis Imperfecta Fail to Meet Primary Endpoints
London & Novato, Calif. — December 2025 Mereo BioPharma Group plc (NASDAQ: MREO) and Ultragenyx Pharmaceutical Inc. (NASDAQ:…
The Best Feeling Is When Our Drugs Succeed”: Dame Emma Walmsley Reflects on GSK’s Legacy of Innovation
London | December 2025 GlaxoSmithKline (GSK) today highlighted a defining reflection from its outgoing Chief Executive Officer, Dame…
Neuroscience Biopharma in Transformation: Pipeline and Commercial Dynamics Reshape the Industry
Washington, D.C. — The neuroscience segment is undergoing a significant strategic transformation, driven by breakthroughs in neurodegenerative, psychiatric,…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26 the Turning Point Where AI Becomes Industrial-Scale Drug Discovery?
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened with a defining…
Lantern Pharma Secures FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas, Expanding AI-Driven Precision Oncology Strategy
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food…
